We found that the previously established pleiotropy between genetic risk for IA and the genes targeted by anti-epileptic drugs is not driven directly by an increased predisposition for epilepsy also affecting IA risk but is partly explained by variation in gene expression of CNNM2. This evidence concerns the gene CNNM2 and epilepsy.